Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Berkeley Heartlab Enters into Agreements with Proven Diagnostics and Geisinger Medical Center to Provide Testing for Cardiovascular Disease
Portfolio of ExcellenceSM agreements will provide Proven Diagnostics customers with access to certain Berkeley HeartLab tests and services, including KIF6

BURLINGAME, CA, and BETHLEHEM, PA - October 28, 2009

Berkeley HeartLab (BHL), a subsidiary of Celera Corporation (NASDAQ:CRA), announced today that it has entered into collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service recently launched by Geisinger Health System.

Through a co-marketing agreement, Proven Diagnostics will provide select diagnostic tools from BHL's menu of proprietary cardiovascular tests and services. Aimed at optimizing cardiovascular treatment, these include BHL's 4myheart cardiovascular disease management program.

Also, Proven Diagnostics and Geisinger Medical Center will be the first external clinical laboratories to have access to KIF6, BHL's proprietary genetic test. The KIF6 gene encodes kinesin-like protein 6 (KIF6). Published research studies have shown an association between KIF6 and cardiovascular risk and statin benefit1-4. This agreement allows Proven Diagnostics and Geisinger Medical Center to offer a more personal treatment approach for those with cardiovascular disease. Testing under the agreement will be performed by BHL.

These agreements were made under Proven Diagnostic's Portfolio of Excellence program. Proven Diagnostics seeks highly specialized laboratories to strengthen its growing menu of laboratory tests. In addition, Proven believes that agreements such as these help ensure that patients receive the most advanced cardiovascular laboratory testing.

Financial terms of the agreements were not disclosed.

"We are delighted to be working with Berkeley HeartLab as we incorporate their proprietary cardiovascular tests into our menu. For instance, KIF6 testing helps our physicians identify patients at elevated risk for cardiovascular disease and help guide disease management," said Candice Miller, Chief Executive Officer, Proven Diagnostics.

"By combining Proven Diagnostics' leading capabilities with our innovative content and services, such as KIF6 and 4myheart, we believe we provide a more personal approach to cardiovascular disease management," said Chris Hall, Senior Vice President, Berkeley HeartLab. "We have a number of other genetic discoveries that we believe could improve the treatment of cardiovascular disease, and we're delighted to be moving this forward by providing tests and services to the betterment of Proven Diagnostics' customers."

As part of Geisinger Health System, Proven Diagnostics has embraced the notion of innovation - one area that has garnered Geisinger national attention from the media and from President Barack Obama. And Proven Diagnostics is taking an innovative approach to its delivery of services, with programs such as the Portfolio of Excellence.

ABOUT PROVEN DIAGNOSTICS and GEISINGER HEALTH SYSTEM
Proven Diagnostics is a new clinical diagnostic laboratory service provided by Geisinger Health System that is designed to provide medical professionals access to a wide array of clinical laboratory services. These services include microbiology, biochemical and hematology testing, esoteric genetic and allergy tests, and anatomical pathology. Proven Diagnostics combines new and trusted technologies with outstanding customer service in support of physicians and their patients. For more information about Proven Diagnostics, please visit www.provendiagnostics.com.

Founded in 1915, Geisinger Health System is one of the nation's largest integrated health services organizations. Serving more than two million residents throughout central and northeastern Pennsylvania, the physician-led organization is at the forefront of the country's rapidly emerging electronic health records movement. Geisinger is comprised of two medical centers, a children's hospital, a 740-member physician group practice, a not-for-profit health insurance company, and the Henry Hood Center for Health Research - dedicated to creating innovative new models for patient care, satisfaction and clinical outcomes.

ABOUT BERKELEY HEARTLAB and CELERA
Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Celera also commercializes a wide range of molecular diagnostic products through Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "will," "should," "anticipate," "may," "could," and "intend," among others. These forward-looking statements are based on Celera's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Celera notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of our business include, but are not limited to, the risks and uncertainties that: (1) the agreements with Proven Diagnostics and Geisinger Medical Center may be terminated; (2) the risk that the marketing program and testing services contemplated by these agreements will not result in increased sales; and (3) the uncertainty that any testing services will be accepted and adopted by the market, including the risk that that these testing services will not be competitive with testing services offered by other companies, or that users will not be entitled to receive adequate reimbursement for these testing services from third party payers such as private insurance companies and government insurance plans. The foregoing list sets forth some, but not all, of the factors that could affect Celera's ability to achieve results described in any forward-looking statements. For additional information about the risks and uncertainties that Celera faces and a discussion of its financial statements and footnotes, see documents filed by Celera with the SEC, including its transition report on Form 10-KT and all subsequent periodic reports. All information in this press release is as of the date of the release, and Celera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Copyrightę 2009. Celera Corporation. All Rights Reserved. Celera is a registered trademark of Celera Corporation or its subsidiaries in the U. S. and/or certain other countries.

References

1. Iakoubova OA et al. (2008) Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 51(4):435-43.

2. Iakoubova OA et al. (2008) Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 51(4):449-55.

3. Shiffman D et al. (2008) Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 28(1):173-9.

4. Shiffman D et al. (2008) A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol. 51(4):444-8.


Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.